{
    "Trade/Device Name(s)": [
        "N Latex FLC kappa",
        "N Latex FLC lambda",
        "N Latex FLC kappa assay",
        "N Latex FLC lambda assay"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Products GmbH",
    "510(k) Number": "K190879",
    "Predicate Device Reference 510(k) Number(s)": [
        "K171742",
        "K182098"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DFH",
        "DEH"
    ],
    "Summary Letter Date": "April 3, 2019",
    "Summary Letter Received Date": "April 4, 2019",
    "Submission Date": "April 3, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.5550"
    ],
    "Regulation Name(s)": [
        "Immunoglobulin (light chain specific) immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Free light chain kappa",
        "Free light chain lambda"
    ],
    "Specimen Type(s)": [
        "Serum",
        "EDTA-plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Atellica CH Analyzer",
        "BN II System",
        "BN ProSpec"
    ],
    "Method(s)/Technology(ies)": [
        "Particle-enhanced immunoassay",
        "Turbidimetry",
        "Nephelometry"
    ],
    "Methodologies": [
        "Quantitative determination",
        "Agglutination",
        "Absorbance measurement"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Supplementary reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Siemens N Latex FLC kappa and lambda assays for quantitative determination of free light chains using immunoassay on Atellica CH and BN platforms",
    "Indications for Use Summary": "In vitro diagnostic reagents for quantitative determination of free light chains (kappa or lambda) in human serum and EDTA-plasma, used as an aid in diagnosis and monitoring of multiple myeloma and amyloidosis alongside other laboratory and clinical findings",
    "fda_folder": "Immunology"
}